Armata Pharmaceuticals, Inc. ARMP
3.89 USD +0.14 (+3.73%)
At closeNov 11, 2026, 4:00 PM EST
3.89 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
3.64 Day range 3.89
2.75 52-week range 14.98
- YTD
- -38.06%
- 1 year
- -42.37%
News
prnewswire.com Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States Issued patents provide intellectual property protection for clinical candidates, AP-SA02 and AP-PA02, until at least 2041 LOS ANGELES, Oct. 7, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 90.6% to $3.87 during Wednesday's after-market session. The market value of their outstanding shares is at $1.7 million. Greenland Mines…
benzinga.com Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program Armata Pharmaceuticals Inc. (AMEX:ARMP) shares are trading lower on Wednesday as traders digest additional non-dilutive funding tied to its lead bacteriophage program.
benzinga.com Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program Armata Pharmaceuticals technical headwinds overshadow a $3.7 million Department of Defense grant funding its Phase 3 bacteriophage program.
benzinga.com HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $15 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:ARMP) with a Buy and maintains $15 price target.
benzinga.com Armata Pharmaceuticals Receives Additional $3.7M In Non-dilutive Funds From US Department Of War For Phase 3 Development Program For AP-SA02 Importantly, the $3.7 million represents the first funding received specifically for Phase 3 execution pursuant to a previously announced DoW award, received through the Medical Technology Enterprise…
prnewswire.com Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aureus bacteremia New commitment is incremental to previously announced DoW funding and expands total…
prnewswire.com Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates Controlled manufacturing reproducibly maintains defined genetic diversity across AP-SA02 clinical drug product lots Oral presentation scheduled for today Monday, Sept. 21, 2026 at the 20 th…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million. Eocene (NASDAQ:EOCN) shares rose…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics…
benzinga.com Armata Pharmaceuticals Receives FDA Breakthrough Therapy Designation For Its Intravenously Administered Staphylococcus Aureus Multi-Phage Product Candidate AP-SA02 Designation for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus ("MSSA") or methicillin-resistant S. aureus ("MRSA"). Breakthrough Therapy designation is…
prnewswire.com Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over available therapies…
prnewswire.com Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference LOS ANGELES, Sept. 10, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of…
prnewswire.com Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials LOS ANGELES, Sept. 3, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of…
benzinga.com Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.45) by 38.64 percent. This is a 40 percent increase over losses of…
prnewswire.com Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update LOS ANGELES, Aug. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of…
zacks.com Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar? Armata Pharmaceuticals (ARMP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further…
benzinga.com Why Is Armata Pharma Stock Gaining Monday? ARMP stock jumps 10% as Armata Pharmaceuticals prepares its AP-SA02 multi-phage candidate for a pivotal Phase 3 trial in late 2026.
benzinga.com Armata Pharma Promotes David House To CFO Executive Leadership UpdateArmata also announced the promotion of David House to Chief Financial Officer. Mr. House has served as the Company's Senior Vice President, Finance and Principal Financial…
benzinga.com Armata Announces Significant Clinical, Regulatory, Manufacturing And Operational Progress Supporting Advancement Of AP-SA02 Toward Planned Phase 3 Superiority Study For Adjunct Treatment Of Complicated Bacteremia FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meetingFour AP-SA02 engineering runs completed; clinical trial material production is the next…
prnewswire.com Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02 FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting Four AP-SA02 engineering runs completed; clinical trial material production is the next…- benzinga.com Armata Pharma Receives Agreement From FDA On Agreed Initial Pediatric Study Plan Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patientsLOS ANGELES, July 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals,…
prnewswire.com Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients LOS ANGELES, July 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals,…
benzinga.com Armata Pharma Receives Additional $2.5M Of Non-Dilutive DoD Funding Via Medical Technology Enterprise Consortium, Managed By Naval Medical Research Command Supports Phase 3 readiness of AP-SA02Non-dilutive DoD funding totals $28.7M to dateLOS ANGELES, June 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the
prnewswire.com Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02 Supports Phase 3 readiness of AP-SA02 Non-dilutive DoD funding totals $28.7M to date LOS ANGELES, June 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the…- benzinga.com Armata Pharmaceuticals Q1 EPS $(3.16) Misses $(0.38) Estimate, Sales $789.000K Up From $491.000K YoY Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(3.16) per share which missed the analyst consensus estimate of $(0.38) by 731.58 percent. This is a 1480 percent decrease over losses…
prnewswire.com Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update Entered into secured credit agreement with Innoviva for $25 million maturing in 2029 LOS ANGELES, May 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the…- benzinga.com Armata Pharmaceuticals Granted FDA's Fast Track Designation For AP-SA02 To Treat Bacterial Infections Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage…
prnewswire.com Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development Advances AP-SA02…- benzinga.com Armata Pharmaceutics Announces Publication Of Paper In 'Communications Biology,' A Peer-Reviewed Journal From Nature Portfolio The publication, titled, "Structural atlas of Pakpunavirus P7-1 reveals determinants of virion stability and genome ejection," describes the structure of phage P7-1, which is included in Armata's…
prnewswire.com Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology" Describes structure of phage P7-1, included in Armata's Pseudomonas aeruginosa phage cocktail, AP-PA02 LOS ANGELES, May 4, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP)…
prnewswire.com Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. LOS ANGELES, April 27, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of public offerings. Other stocks also lower.- benzinga.com Armata Pharmaceuticals Q4 EPS $(3.43) Misses $(0.28) Estimate, Sales $1.085M Beat $750.000K Estimate Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(3.43) per share which missed the analyst consensus estimate of $(0.28) by 1125 percent. This is a 1391.3 percent decrease over losses…
prnewswire.com Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results LOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of…- benzinga.com Armata Pharmaceuticals To Delay Announcement Of Q4, FY25 Financial Results; Provides Corporate Update Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage…
prnewswire.com Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update LOS ANGELES, March 19, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of…- benzinga.com HC Wainwright & Co. Maintains Buy on Armata Pharmaceuticals, Raises Price Target to $15 HC Wainwright & Co. analyst Joseph Pantginis maintains Armata Pharmaceuticals (AMEX:ARMP) with a Buy and raises the price target from $9 to $15.
prnewswire.com Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus QIDP Designation provides for five years of market exclusivity and the potential for fast…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
prnewswire.com Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3study First bacteriophage company to advance a clinical candidate to Phase 3 LOS ANGELES, Jan. 13, 2026…- benzinga.com Jones Trading Initiates Coverage On Armata Pharmaceuticals with Buy Rating, Announces Price Target of $15 Jones Trading analyst Debanjana Chatterjee initiates coverage on Armata Pharmaceuticals (AMEX:ARMP) with a Buy rating and announces Price Target of $15.
- benzinga.com Armata Pharmaceuticals Q3 EPS $(0.74) Misses $(0.42) Estimate, Sales $1.159M Miss $1.380M Estimate Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.42) by 76.19 percent. This is a 393.33 percent decrease over…
- benzinga.com Armata Pharmaceuticals Commissions Good Manufacturing Practice Production Facility In Los Angeles Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session